Letters of Intent from Major Shareholders, Board, and Management to Subscribe for SEK 11 million in Dicot Pharma’s TO 6, Running Until March 31, 2025
Uppsala, Sweden, March 13, 2025. Major shareholders in Dicot Pharma and all members of the board and management holding warrants of series TO 6 have declared their intention to exercise them. This corresponds to a total investment of approximately SEK 11 million, or about 24 percent of the total outstanding warrants. The subscription period for TO 6 runs March 17 until March 31, 2025.
“It is very pleasing that we are once again seeing strong support from our major shareholders, board and management. This confidence means a lot and it feels extra valuable to be able to announce this even before the subscription period has begun”, says Elin Trampe, CEO.
One warrant of series TO 6 entitles to subscribe for two new shares at SEK 0.19 per share. To prevent the warrants from expiring worthless, the holder must actively subscribe for shares by March 31, 2025, or alternatively sell the warrants by March 27, 2025.
If all warrants are exercised for the subscription of new shares, Dicot Pharma will receive approximately SEK 45.7 million before issuance costs.
The terms and conditions regarding the warrants are available on Dicot Pharma’s website www.dicotpharma.com.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma’s business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.
Dicot Pharma is listed on Nasdaq First North and has approximately 9,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.
This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.